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Abstract
Background: Inhaled corticosteroids (ICS) are the cornerstone of asthma therapy. The ICS-to-total-asthma-medication
ratios, calculated from claims data, indicate potentially risky disease management in asthma. Our aim was to assess the
utility of ICS-to-total-asthma-medication ratios from primary care electronic medical records (EMRs) in detecting patients
at risk of asthma exacerbation, as approached by prescription of oral corticosteroids and/or antibiotics.
Methods: Retrospective cohort studies were identified, using the Health Improvement Network general practice
database (THIN, United Kingdom) and the Cegedim Longitudinal Patient Data (France). We selected asthma patients
aged 16–40 years, with≥ 4 prescriptions for asthma medications in 2007 and≥ 1 prescription in 2008. For each
country, three groups were defined according to ratio value in 2008: 0% (non-ICS users), <50% (low-ICS-ratio group)
and ≥50% (high-ICS-ratio group). Outcomes were marker of asthma exacerbations: systemic corticosteroids and
antibiotics. They were compared between groups in each country.
Results: Among 38,637 British and 4,587 French patients, higher numbers of prescriptions per patient of systemic
corticosteroids, antibiotics and total asthma medications were observed in the low-ICS-ratio groups compared to
other groups (p < 0.0001 for each outcome in both countries). Likewise, low-ICS-ratio patients had more medical
contacts (p < 0.0001 in both countries), suggesting poorly controlled asthma. ICS-treated patients had lower risks
of receiving systemic corticosteroids in 2008 in the high-ICS-ratio group, compared to the low-ICS-ratio group:
RR = 0.54, 95%CI = [0.50-0.57] and RR = 0.78, 95%CI = [0.67-0.91] in the UK and France, respectively.
Conclusions: Patients with high ICS-to-total-asthma-medication ratios presented fewer asthma-related outcomes.
The low ICS-to-total-asthma-medication ratio calculated with EMRs data reflects insufficient prescribing of ICS
relative to all asthma medications, which may lead to deteriorated asthma control.
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Background
The controller-to-total-asthma-medication ratio has been
used to assess the quality of asthma care using the United
States claims data [1-3]. Patients with controller-to-total-
asthma-medication ratio values of 50% and higher exhibited
fewer asthma exacerbations than those with lower ratios, as
assessed by proxies such as hospitalizations or visits to
emergency departments [1,3]. Consistent results were also
obtained after restraining controllers to inhaled corticoste-
roids (ICS) and calculating ICS-to-total-asthma-medication
ratios using French claims data [4]. To our knowledge,
controller-to-total-asthma-medication ratios and particu-
larly the ICS-to-total-asthma-medication ratio have not
been computed using prescribing data from primary care
electronic medical records (EMRs), though other ratios
have been studied, such as ICS-to-reliever ratios [5,6] and
controller-to-reliever ratios [7]. Further, the distributions
within the low and high ICS-to-total-asthma-medication
ratio subgroups have been little explored. It is unclear
whether these distributions are homogenous, or if distinct
subgroups with specific characteristics can be identified
within high and/or low-ICS-ratio groups.
Prescribing data reflect health care professional’s
(HCP) diagnoses and decisions and, therefore, provide
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result from both HCP’s prescribing and patients’ compli-
ance with prescription orders. Hence, using prescribing
data, it is possible to assess if high-ICS-ratio patients
present fewer asthma exacerbations than those with
lower ratio values. Further, as prescribing may be af-
fected by the local organization of health care, e.g. na-
tional prescribing guidelines, it was of interest to explore
the relationship between ratios and medical resource
utilisation in countries with two different health care
systems, i.e. France and the United Kingdom (UK). In
the United Kingdom, GPs are employed by the NHS or
by general practices whereas most French primary care
physicians have a liberal status, and their incomes pri-
marily depend on the volume of their activity. In con-
trast, the quality of care impacts British physicians’
salary due to the presence of a pay for performance
scheme. This system rewards general practices that
achieve targets set over a wide range of clinical indica-
tors. For instance, physicians are encouraged to perform
annual disease reviews for their asthma patients, which
include an assessment of disease control [8].
Our objective was to determine whether ICS-to-total-
asthma-medication ratios, computed in primary care
prescribing data, could be used to detect patients at risk
of asthma exacerbation, by comparing prescriptions and
medical contacts between non-ICS users, low- and high-
ICS-ratio groups.
Methods
Study design and data sources
We conducted a database study using primary care elec-
tronic medical records data from the UK and France (The
Health Improvement Network or THIN and Longitudinal
Patient Data or LPD). The data between 1st January 2007
and 31th December 2008 were extracted for all patients
with at least one prescription in 2007 of respiratory drug
ATC: R03. Extractions included patients’ age, gender, and
information on general practitioner visits and medication
prescribing in 2007 and 2008.
THIN collects anonymized longitudinal primary care
patient records including demographic, medical and pre-
scription information at an individual patient level from
participating general practices in the UK that routinely
record these data. The data collection was approved by
the NHS South-East Multi-centre Research Ethics Com-
mittee in 2003. The THIN data were shown to be
generalizable to the UK population [9,10].
To derive data for the French patients, the LPD database
was used. The database includes anonymous data on pa-
tient consultations and prescribed medications. General
practitioners belonging to the LPD Network are representa-
tive of the French GP population based on age, gender and
geographical region. LPD holds an ethical approval fromthe French National Data Protection Authority (CNIL) for
data collection since 2002. As our study utilized anon-
ymized patients data only, no additional ethical approval
was needed.
Cohort selection
We received extractions of patients with at least one
prescribed asthma drug (ATC Classification: R03) in
2007, from THIN (United-Kingdom) and the LPD data-
base (France). From these data, we selected patients
aged between 16 and 40 years who received at least 4
prescriptions for asthma medications in 2007 [11] and
at least one prescription for an asthma medication in
2008. We excluded patients receiving tiotropium dur-
ing the study time frame. Exclusion criteria were used
to limit the presence of patients with chronic obstruct-
ive respiratory disease (COPD). Differentiation of
asthma and COPD can be challenging in primary care.
Additionally, both diseases are mostly treated by the
same drug classes. However, COPD typically occurs
after the age of 40 and tiotropium was one of the few
respiratory drugs specific to COPD at the time of the
study.
ICS-to-total-asthma-medication ratio (ICS/R03)
Respiratory medications included short-acting beta-2-
adrenoreceptor agonists (SABA), anticholinergics,
SABA/anticholinergic fixed combinations, long-acting
beta-2-adrenoreceptor agonists (LABA), inhaled corti-
costeroids (ICS), LABA/ICS fixed combinations, leu-
kotriene receptor antagonists (LTRA), xanthines and
cromones.
The ICS-to-total-asthma-medication ratio constituted
the proportion of prescribed units of ICS out of the over-
all number of respiratory medication units [11] prescribed
during 2008. In French data, we employed units of pre-
scribed medications (i.e., 1 unit = 1 canister for inhaled
therapy or 1 packaging for oral therapy) in the calculation
of the ratios as patients can receive more than one canister/
package with one prescription in France. As the number of
prescribed units was not available in the THIN data for oral
therapy, the ICS-to-total-asthma-medication ratio in the
UK was computed based on the number of prescriptions
recorded. In both countries, LABA/ICS fixed combinations
and not combined ICS were all counted as one ICS unit in
ratios, both in numerator and denominator. Three groups
were defined according to the value of ICS-to-total-
asthma-medication ratio in 2008: R = 0% (non ICS users),
0% < R < 50% (low-ICS-ratio group) and R ≥ 50% (high-
ICS-ratio group).
Outcomes
The outcomes were prescriptions for systemic cortico-
steroids and respiratory antibiotics (beta-lactams, first
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fluoroquinolones). All outcomes were assessed from 1
January 2008 to 31 December 2008.
Statistical analyses
We analysed the data from the UK and France according
to the same statistical analysis plan, in four successive
steps.
a. Distribution of ratios and definition of groups
The distribution of the ICS-to-total-asthma-medication
ratios was first examined. The patients were then
assigned into the ratio groups (non ICS users, low-ICS-
ratio group and high-ICS-ratio group, as defined in the
specific paragraph).b. Univariate analyses
Then, the different groups of patients were
compared according to patients’ age and gender,
number of GP visits, and the total number of
prescribed asthma medications in 2008 (marker of
asthma severity), and the systemic corticosteroids
and antibiotics prescribing levels (outcomes). Chi2
test and ANOVA were used for univariate analyses.c. Multivariate analyses
Multivariate logistic regression models were then
conducted among ICS-treated patients only (low
and high-ICS ratio groups) to determine the adjusted
risk of receiving systemic corticosteroids (respiratory
antibiotics) according to ratio value (high vs. low).
Adjustments were made for age, gender, use of a fixed
LABA-ICS combinations in 2008, and the number of
respiratory medications prescribed in 2008 (<6, ≥ 6).
For all models, the low-ICS-users group was used as
the reference.d. Sensitivity analyses
Sensitivity analyses on prescriptions for systemic
corticosteroids and antibiotics in patients
receiving ≥ 6 prescribed units of respiratory
medications (≥6 prescriptions in the UK) were also
performed in univariate analyses, as some ratios may
be high as a consequence of low prescribing levels of
respiratory medications (small denominator).
Furthermore, in case of clearly distinguishable
subgroups within the low, or within the high-ICS-
ratio group in the main analysis, complementarycomparisons between the different subgroups were
performed in the given group according to patient
number of medical contacts, studied outcomes and
prescribed asthma medications in 2008.All analyses were performed using SAS statistical soft-
ware, version 9.2 (SAS Institute, Cary, North Carolina).
All reported p-values are 2-tailed, with significance level
set at 5%.
Results
The extractions of patients under respiratory therapy in
2007 included 343,156 patients in the UK and 119,265 in
France. After applying inclusion criteria, we identified in
the extractions 38,637 patients (11.2%) in the UK THIN
data (mean age = 29 years, 53% females) and 4,587 patients
(3.8%) in the French LPD data (mean age = 28 years, 54%
females). The ratio distributions for the UK and France are
presented in Figure 1.
The shape of the observed ICS-to-total-medication ratios
distribution was similar in both countries; however there
were differences in the proportion of non ICS users (26% in
France vs. 18% in the UK). In the low-ICS-ratio groups, the
distributions presented a Gaussian-like pattern in both
countries, with a maximal frequency in the 30–39.9%
interval.
More than 40% of British and French patients
belonged to the high-ICS-ratio group (43.3% and 44.7%,
respectively) and three distinct sub-groups were identi-
fied within this group in both countries. We observed a
clear distribution peak right after the 50% threshold, in
the 50–59.9% interval. These patients accounted for 65%
of the high-ICS-ratio group in the UK and 38% in
France. Another sub-population could be identified for
the highest ratio values, the 90% and greater, notably in
France (33% of the high-ICS-ratio group), and to a lesser
extent, in the UK (12% of this group).
The medical resource utilization data for the three
groups are presented in Table 1 and Table 2. The groups
were found to be similar in age and gender. The patients
in the low-ICS-ratio group received more prescriptions
for systemic corticosteroids and antibiotics and visited
GPs more frequently. When the analyses were restricted
to patients with ≥6 prescriptions in the UK (and ≥ 6 pre-
scribed units in France) in 2008, the findings were con-
sistent with the main analyses. Systemic corticosteroids
and LABA/ICS fixed combinations were found to be
prescribed more frequently in France than in the UK.
We were able to identify three subgroups in the high-
ICS-ratio groups (50–59.9%, 60%-89.9%, and ≥90%).
These subgroups were compared in terms of number of
GP visits and prescribed therapy. In both countries, pa-
tients with the highest ratio values (≥90%) were pre-
scribed fewer systemic corticosteroids and antibiotics as
Figure 1 Distribution of ICS-to-total-asthma-medication ratio in the UK (n = 38,637) and in France (n = 4,587).
Laforest et al. BMC Family Practice  (2015) 16:49 Page 4 of 8well as asthma medications, more markedly in the UK,
where these patients also visited their GPs less fre-
quently. The differences between the 50–59.9% and 60–
89.9% subgroups, however, were less pronounced for
systemic corticosteroids. We did not observe any appar-
ent uniform downward trend in number of systemic cor-
ticosteroids and antibiotic prescriptions in the three
subgroups as the ratio increased (Table 3).
In the multivariate main analyses performed on the
UK data, the high-ICS-ratio group had a significantly
lower risk of receiving a prescription for systemic corti-
costeroids or antibiotics than the low-ICS-ratio group.
The conclusions for French patients were similar,suggesting that there was an association between the
high-ICS-to-total-asthma-medication ratio and lower
number of systemic corticosteroids prescriptions, while
decreased risks of receiving antibiotics were also ob-
served. It approached significance in France (Table 4).
Discussion
In this database study utilizing primary care data we calcu-
lated ICS-to-total-asthma-medication ratios and assessed
asthma related outcomes in more than 40,000 patients
from the UK and France. Although not identical, the distri-
butions of therapeutic ratios presented similarities in both
countries, with a Gaussian-like pattern in the low-ICS-ratio
Table 1 Medical resource utilization and prescribed










Number of patients 6,996 14,903 16,738
Age, years (mean) 28.9 29.4 29.4 <0.0001
Gender, female (%) 49.6% 53.8% 55.1% <0.0001
Number of GP visits (mean) 5.5 7.7 6.6 <0.0001
Prescribed therapy
Number of respiratory medication
prescriptions (mean)
3.6 12.9 6.9 <0.0001
Patients with ≥ 1 prescription
of LABA-
- 41.1% 44.3% <0.0001
ICS fixed combination (%)
Number of short-acting beta
agonists prescriptions (mean)
3.4 6.7 2.7 <0.0001
Systemic corticosteroids
Patients with≥ 1 prescription (%) 6.2% 22.5% 12.7% <0.0001
Number of prescriptions (mean) 0.1 0.5 0.2 <0.0001
Antibiotics(a)
Patients with≥ 1 prescription (%) 34.5% 47.9% 41.4% <0.0001
Number of prescriptions (mean) 0.7 1 0.8 <0.0001
Patients with at least 6 prescriptions of
respiratory medications in 2008
Number of patients 1,384 11,835 8,391
Systemic corticosteroids
Patients with≥ 1 prescription (%) 8.2% 24.6% 15.5% <0.0001
Number of prescriptions (mean) 0.2 0.5 0.3 <0.0001
Antibiotics(a)
Patients with≥ 1 prescription (%) 35% 49.3% 44.8% <0.0001
Number of prescriptions (mean) 0.8 1.1 0.9 <0.0001
(a)Beta-lactams, cephalosporins (first to third generation), macrolides
and fluoroquinolones.
Table 2 Medical resource utilization and prescribed










Number of patients 1,176 1,358 2,053
Age, years (mean) 28.1 28.4 29.5 <0.0001
Gender, female (%) 54.7% 53.5% 55% 0.66
Number of GP visits (mean) 5.3 6.5 5.6 <0.0001
Prescribed therapy(a)
Number of respiratory medication
units (mean)
5.1 18.6 8.7 <0.0001
Patients with≥ 1 prescription of
LABA-ICS fixed combination (%)
- 71.2% 81.2% <0.0001
Number of short-acting beta
agonists units (mean)
2.9 6 1.8 <0.0001
Systemic corticosteroids
Patients with≥ 1 prescription (%) 21.9% 36.1% 30.5% <0.0001
Number of units (mean) 0.6 1.2 0.8 <0.0001
Antibiotics(b)
Patients with≥ 1 prescription (%) 46.5% 55.7% 53% <0.0001
Number of units (mean) 1.3 2.1 1.7 <0.0001
Patients with at least 6 prescriptions of
respiratory medications in 2008
Number of patients 367 1,153 1,152
Systemic corticosteroids
Patients with≥ 1 prescription (%) 21% 36% 32.1% <0.0001
Number of units (mean) 0.7 1.2 1 0.05
Antibiotics(b)
Patients with≥ 1 prescription (%) 43.9% 55.3% 52% 0.0006
Number of units (mean) 1.3 2 1.8 <0.0001
(a)Canisters for inhaled therapy and packages for oral therapy in France.
(b)Beta-lactams, cephalosporins (first to third generation), macrolides
and fluoroquinolones.
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France. In both countries, patients in the low-ICS-ratio
group (<50%) were prescribed more systemic corticoste-
roids, antibiotics and asthma medications than patients
from other groups. These patients also visited their GPs
more frequently than the high-ICS-ratio group.
Our findings are consistent with prior research on the
controller-to-total-asthma-medication ratios performed
in claims data using asthma-related hospital contact as
outcome [1,3]. A lower risk of being dispensed systemic
corticosteroids was also observed in patients with high-
ICS-to-total-medication ratios compared to those with
lower ratios [4]. Also, these findings are in line with a
better asthma control, as observed in patients with
higher ratios (≥50%) by validation studies [12,13].The interpretation of ratio values computed from pri-
mary care prescribing data differs from that of claims
data. A high ratio in prescribing data may not reflect
patients’ actual exposure to ICS, as prescriptions not
dispensed by community-pharmacies are included in
analyses. Conversely, unlike claims databases, a low
ICS-to-total-asthma-medication ratio in primary care
data is fully attributable to insufficient prescribing of
ICS by physicians, irrespective of patients’ behaviour,
except in case of fragmented care.
Our findings suggest that some GPs insufficiently pre-
scribe ICS and that such prescribing patterns may facili-
tate asthma exacerbations [14]. Utilising General
Practice records to identify patients that receive insuffi-
cient ICS treatment relative to overall asthma therapy
and introducing corrective interventions can, therefore,
help decrease the burden of asthma.
Table 3 Complementary analyses: Medical resource utilization and prescribed medications in 2008 in the 3 subgroups
identified within the high-ICS-ratio group
50% ≤ R < 60% 60% ≤ R < 90% 90% ≤ R p-value
UK
Number of patients 10,929 3,715 2,094
Number of respiratory medication prescriptions (mean) 7.5 6.86 3.62 <0.0001
Systemic corticosteroids
Patients with ≥ 1 prescription (%) 12.7% 14.7% 8.9% <0.0001
Number of prescriptions (mean) 0.2 0.24 0.16 0.0006
Antibiotics(a)
Patients with ≥ 1 prescription (%) 41.9% 43.4% 35.5% <0.0001
Number of prescriptions (mean) 0.8 0.86 0.7 0.0001
Patients with ≥ 1 prescription of LABA-ICS fixed combination (%) 38.9% 56.2% 51% <0.0001
Number of GP visits (mean) 6.5 7.2 5.9 <0.0001
France(b)
Number of patients 783 597 673
Number of respiratory medication prescriptions units (mean) 9.61 11 5.67 <0.0001
Systemic corticosteroids
Patients with ≥ 1 prescription (%) 29.9% 33.3% 28.7% 0.178
Number of units(b) (mean) 0.84 0.82 0.77 0.811
Antibiotics(a)
Patients with ≥ 1 prescription (%) 50.7% 55.8% 53.3% 0.17
Number of units(b) (mean) 1.61 1.91 1.52 0.0159
Patients with ≥ 1 prescription of LABA-ICS fixed combination (%) 75.5% 89.9% 82% <0.0001
Number of GP visits (mean) 5.4 5.8 5.6 0.273
(a)Beta-lactams, cephalosporins (first to third generations), macrolides and fluoroquinolones.
(b)Canisters for inhaled therapy and packages for oral therapy.
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lers in persistent asthma, particularly ICS. Patients un-
treated by ICS were more numerous in France, which
might be explained by a poorer adherence to the guidelines
than in the UK. However, it could also be that some non-
ICS patients might have intermittent or milder asthma
while others might be treated with LTRAs monotherapy.
The non-ICS group was characterised by a lower numberTable 4 Logistic regression models: Risks of receiving in 2008
and risk of receiving ≥ one prescription of antibiotics (model
(non ICS users excluded)
Model 1: Risks of receiving in 2008 ≥
prescription of systemic corticosteroi
Adjusted OR(a) 95% C
UK (n = 31,641)
Low ratio (0% < R < 50%) 1 -
High ratio (R ≥ 50%) 0.54 0.50-0
France (n = 3,411)
Low ratio (0% < R < 50%) 1 -
High ratio (R ≥ 50%) 0.78 0.67-0
(a)Adjusted for age, gender, ≥ 1 dispensing of LABA-ICS fixed combination, the numof prescriptions for systemic corticosteroids as well as for
asthma medications.
In patients receiving ICS, we selected the 50% ratio
value as a cut-off to classify the patients into the low-
ICS-ratio and the high-ICS-ratio group. Altogether,
more than one third of all patients were in the low-ICS-
to-total-asthma-medication group. Patients from this
group were prescribed more asthma medications,≥ one prescription of systemic corticosteroids (model 1)
2), according to ratio groups in ICS-treated patients
one
ds
Model 2: Risks of receiving in 2008 ≥ one
prescription of antibiotics





ber of dispensed respiratory medication classes in 2008 (<6, 6+).
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frequently. Our multivariate models suggested that,
compared to these patients, the high-ICS-ratio group
presented lower risks of both receiving systemic cortico-
steroids and antibiotics (Table 4). It cannot be excluded
that the increased resource utilisation in the low-ICS ratio
may be partly due to a higher severity of asthma, as
suggested by the higher number of asthma medications
prescribed to this group. Also, our findings were not sub-
stantially affected after restricting the analyses to patients
with at least 6 prescribed units of respiratory medications
(prescriptions in the UK), confirming the robustness of our
findings. Additionally, as ratio denominator comprises all
respiratory medications prescribed during the 12-month
period, the severity of asthma, as measured by intensity of
treatment, is partially accounted for [2,17], thus further lim-
iting the risk of an indication bias.
The low-ICS-ratio patients also tended to be prescribed
fewer fixed LABA-ICS fixed combinations, particularly in
France. Patients prescribed fixed LABA-ICS combinations
may require less SABA and non-combined LABA which in
turn decreases the ratio denominator. This higher use of
fixed combinations in the high ICS ratio group has been
observed previously [18].
Upon examining the distribution within the high-ICS-
ratio group we identified three subgroups (50–59.9%,
60–89.9%, ≥90%). In France the three subgroups did not
differ significantly from one another in terms of systemic
corticosteroids, antibiotics prescribing and medical visits. In
the UK, however, the ≥90% subgroup patients received
fewer systemic corticosteroids and antibiotics, while they
visited their GPs less frequently. Also, the number of pre-
scriptions for all respiratory medications was lower in pa-
tients in this subgroup with the highest ratios (≥90%), both
in the UK and in France, which could suggest a milder
asthma or less regular prescribing. The 90% threshold,
however, is not clinically meaningful in assessing the quality
of care as only a marginal proportion of patients with a
milder disease can be identified. Therefore, our data sup-
ports the choice of the 50% threshold value, as the out-
comes in the three high-ICS-ratio subgroups showed no
steady trend towards improvement in asthma control with
increasing ICS-to-total-asthma-medication ratio. A pos-
sible direction for further research will be to bring
together primary care prescribing data, medication dis-
pensation data and patient-reported data to determine the
best cut-off values for ICS-to-total-asthma-medication
ratio threshold.
We were not able to use an identical ratio definition in
both countries due to differences in the data on pre-
scribed medications. The UK data did not contain infor-
mation allowing counting the number of prescribed
packages for oral therapy. We therefore calculated the
ratios for the UK patients using the number of ICSprescriptions in the numerator and the number of all
respiratory medication prescriptions in the denominator.
However, this potential bias should not have affected the
validity of this definition as both the numerator and de-
nominator were similarly approximated. Despite these
discordant definitions, consistent results were obtained
between the two countries. Our definitions of ratio did
not take into account the dosing of ICS canisters nor the
potency of the molecule, hence can be considered ‘un-
weighted’. In comparison with a more elaborate alterna-
tive [19], this turned out to be more discriminating, as
severe patients at a higher risk of asthma exacerbations
tend to receive more potent ICS and, therefore, would
likely qualify in the high-ICS ratio group. Further, the
ratio that can be obtained by a more basic calculation
has a practical benefit as it can be computed in practice
without elaborate programming.
Our study has some limitations. As we wanted to in-
clude patients receiving regular prescribing for asthma,
our study population corresponded to a minority of se-
lected persistent asthmatics with a close supervision in
primary care. Thus, these patients were not representa-
tive of the overall population of asthmatics. Prescriptions
from physicians not affiliated to the study networks were
not available in the database. Henceforth, the number of
prescriptions might have been underestimated if frag-
mented care or partial supervision by specialists did
occur. Nevertheless, we believe that this bias may not
affect our conclusions. Firstly, analyses were conducted
in patients with at least four annual prescriptions of
asthma medications during baseline period (2007). Then,
the underestimation of prescriptions should be similar in
both numerator and denominator of therapeutic ratios.
As another limitation, major outcomes such as hospital
admissions or emergency room visits were not available
in these databases. We used proxies, such as systemic
corticosteroids and antibiotics prescriptions, to identify
asthma exacerbations. Unlike systemic corticosteroids,
antibiotics however are not listed as outcomes for
asthma [20,21], though they are commonly used in
asthma [22,23]. Nonetheless, the consistency of our data
on systemic corticosteroids and antibiotics support the
validity of our results. Finally, the ICS-to-total-asthma-
medication ratio did not take into account leukotriene-
receptor antagonists. Our preceding studies nonetheless
showed that the addition of LTRA to ICS in the numer-
ator yielded close conclusions regarding the ability to
detect at-risk patients [4,13].
Based on these findings, it should be of interest to verify
whether patients of the low ratio group are more likely to
be supervised by specific profiles of GPs. In such case, the
reasons that lead these physicians to prescribe a limited
amount of ICS compared to other anti-asthma drugs needs
to be better understood. Then, targeted educational
campaigns should be carried out in primary care to im-
prove the quality of prescribing in asthma, specifically
among low prescribers of ICS.
Conclusions
In conclusion, our findings suggest that insufficient
prescribing of ICS in primary care may lead to asthma
exacerbations and, consequently, increased medical re-
source utilization. Quality of care could improve if the
ICS-to-total-asthma-medications ratios were used to
screen irregular use of ICS in asthma before potential
occurrence of adverse outcomes.
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